AR082590A1 - Inhibidores de la tirosina-quinasa de bruton - Google Patents

Inhibidores de la tirosina-quinasa de bruton

Info

Publication number
AR082590A1
AR082590A1 ARP110102870A ARP110102870A AR082590A1 AR 082590 A1 AR082590 A1 AR 082590A1 AR P110102870 A ARP110102870 A AR P110102870A AR P110102870 A ARP110102870 A AR P110102870A AR 082590 A1 AR082590 A1 AR 082590A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
heterocycloalkyl
cycloalkyl
halogen
Prior art date
Application number
ARP110102870A
Other languages
English (en)
Inventor
Steven Joseph Berthel
Roland J Billedeau
Christine E Brotherton-Pleiss
Fariborz Firooznia
Stephen Deems Gabriel
Xiaochun Han
Ramona Hilgenkamp
Saul Jaime-Figueroa
Brulent Kocer
Francisco Javier Lopez-Tapia
Yan Lou
Lucja Orzechowski
Timothy D Owens
Jenny Tan
Peter Michael Wovkulich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45565273&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082590(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR082590A1 publication Critical patent/AR082590A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Los compuestos aquí descritos son útiles para modular la actividad de la Btk y para tratar enfermedades asociadas, con una actividad excesiva de la Btk. Los compuestos son también útiles para tratar enfermedades inflamatorias y autoinmunes asociadas con una proliferación aberrante de las células B, por ejemplo la artritis reumatoide. Se describen también composiciones que contienen los compuestos de la fórmula (1) y por lo menos un vehículo, diluyente o excipiente.Reivindicación 1: Un compuesto de la fórmula (1), en la que - - - - - es un enlace sencillo o un doble enlace; X es CH, CH2 o N; R es H, -R1, -R1-R2-R3, -R1-R3 o -R2-R3; R1 es arilo, heteroarilo, heteroarilo bicíclico, cicloalquilo o heterocicloalquilo, cada uno de ellos está opcionalmente sustituido por uno o más alquilo inferior, hidroxi, hidroxialquilo inferior, alcoxi inferior, halógeno, nitro, amino, amido, ciano, oxo o haloalquilo inferior; R2 es -C(=O), -C(=O)O, -C(=O)NR2’, -NHC(=O)O, -C(R2’)2, -O, -S, -C(=NH)NR2’ o -S(=O)2; cada R2’ es con independencia H o alquilo inferior; R3 es H o R4; R4 es alquilo inferior, haloalquilo inferior, alcoxi inferior, amino, (alquilo inferior)-amino, cicloalquilamino, di(alquilo inferior)-amino, arilo, arilalquilo, alquilarilo, heteroarilo, alquil-heteroarilo, heteroaril-alquilo, cicloalquilo, alquil-cicloalquilo, cicloalquil-alquilo, heterocicloalquilo, alquil-heterocicloalquilo, heterocicloalquil-alquilo, cicloalquilo bicíclico, heterocicloalquilo bicíclico, espirocicloalquilo, espiroheterocicloalquilo, o espiroheterocicloalquilo bicíclico, cada uno de ellos está opcionalmente sustituido por uno o más alquilo inferior, halógeno, (alquilo inferior)-amino, di(alquilo inferior)-amino, hidroxi, hidroxialquilo inferior, alcoxi inferior, alcanoílo inferior, halógeno, nitro, amino, amido, acilo, ciano, oxo, sulfonilo, alquilsulfonilo inferior, guanidino, hidroxil-amino, carboxi, carbamoílo, carbamato, haloalcoxi inferior, heterocicloalquilo o haloalquilo inferior; dos grupos alquilo inferior juntos pueden formar un anillo; Y4 es Y4a, Y4b, Y4c o Y4d; Y4a es H o halógeno; Y4b es alquilo inferior, opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por haloalquilo inferior, halógeno, hidroxi, amino, ciano y alcoxi inferior; Y4c es cicloalquilo inferior, opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por alquilo inferior, haloalquilo inferior, halógeno, hidroxi, amino, ciano y alcoxi inferior; y Y4d es amino, opcionalmente sustituido por uno o más alquilo inferior, alcoxi alquilo inferior o hidroxialquilo inferior; o una sal farmacéuticamente aceptable del mismo.
ARP110102870A 2010-08-12 2011-08-08 Inhibidores de la tirosina-quinasa de bruton AR082590A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37288710P 2010-08-12 2010-08-12
US201161497093P 2011-06-15 2011-06-15

Publications (1)

Publication Number Publication Date
AR082590A1 true AR082590A1 (es) 2012-12-19

Family

ID=45565273

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102870A AR082590A1 (es) 2010-08-12 2011-08-08 Inhibidores de la tirosina-quinasa de bruton

Country Status (21)

Country Link
US (2) US8481540B2 (es)
EP (1) EP2603500B1 (es)
JP (1) JP5823518B2 (es)
KR (1) KR101546167B1 (es)
CN (1) CN103153984B (es)
AR (1) AR082590A1 (es)
AU (1) AU2011288489A1 (es)
BR (1) BR112013003114A2 (es)
CA (1) CA2807634A1 (es)
CL (1) CL2013000391A1 (es)
CO (1) CO6620025A2 (es)
EA (1) EA201390207A1 (es)
EC (1) ECSP13012437A (es)
ES (1) ES2528371T3 (es)
HK (1) HK1186186A1 (es)
MA (1) MA34465B1 (es)
MX (1) MX2013001715A (es)
PE (1) PE20131153A1 (es)
SG (1) SG187747A1 (es)
WO (1) WO2012020008A1 (es)
ZA (1) ZA201300705B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
KR101663335B1 (ko) 2008-12-22 2016-10-06 메르크 파텐트 게엠베하 6-（1-메틸-1ｈ-피라졸-4-일）-2-｛3-［5-（2-모르폴린-4-일-에톡시）-피리미딘-2-일］-벤질｝-2ｈ-피리다진-3-온디히드로겐포스페이트의 신규한 다형체 및 이의 제조 방법
MX345170B (es) 2011-05-17 2017-01-19 Hoffmann La Roche Inhibidores de la tirosina-cinasa de bruton.
KR20140052032A (ko) * 2011-08-17 2014-05-02 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
EA027561B1 (ru) 2011-11-03 2017-08-31 Ф.Хоффманн-Ля Рош Аг Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
BR112014010391A2 (pt) 2011-11-03 2017-04-18 Hoffmann La Roche composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP2773632B1 (en) * 2011-11-03 2017-04-12 F. Hoffmann-La Roche AG 8-fluorophthalazin-1(2h)-one compounds as inhibitors of btk activity
PL2861566T3 (pl) 2012-06-13 2017-06-30 F.Hoffmann-La Roche Ag Nowy diazaspirocykloalkan i azaspirocykloalkan
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
AU2013299557B2 (en) 2012-08-10 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
BR112015005361A2 (pt) * 2012-09-13 2017-07-04 Hoffmann La Roche inibidores de tirosina quinase de bruton
HUE045797T2 (hu) 2012-09-25 2020-01-28 Hoffmann La Roche Hexahidropirrolo[3,4-c]pirrol-származékok és rokonvegyületek mint autotaxin (ATX) inhibitorok, valamint a lizofoszfatidsav (LPA) termelés inhibitorai, például vesebetegségek kezelésére
US9458105B2 (en) * 2012-11-16 2016-10-04 Hoffmann-La Roche Inc. Inhibitors of Bruton's tyrosine kinase
CA2891634A1 (en) * 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
MX2015010983A (es) * 2013-03-05 2015-10-26 Hoffmann La Roche Inhibidores de tirosina-cinasa de bruton.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
DK2989106T3 (en) 2013-04-25 2017-03-20 Beigene Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
EP3016943B1 (en) * 2013-07-03 2019-08-21 F. Hoffmann-La Roche AG Heteroaryl pyridone and aza-pyridone amide compounds
HUE060420T2 (hu) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
KR101813830B1 (ko) 2013-12-05 2017-12-29 에프. 호프만-라 로슈 아게 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
JP6294490B2 (ja) 2013-12-13 2018-03-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
CA2942204A1 (en) 2014-03-12 2015-09-17 Novartis Ag Combination comprising a btk inhibitor and an akt inhibitor
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
WO2015149056A1 (en) * 2014-03-28 2015-10-01 Board Of Regents, The University Of Texas System Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury
EP3160505A4 (en) 2014-07-03 2018-01-24 BeiGene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
WO2016209996A1 (en) 2015-06-23 2016-12-29 University Of Oregon Phosphorus-containing heterocycles and a method for making and using
AU2016316717B2 (en) 2015-09-04 2021-02-18 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
RU2018114289A (ru) 2015-09-24 2019-10-24 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов аутотаксина (atx)
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
CA2991612A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
CR20180072A (es) 2015-09-24 2018-02-26 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
JP6993056B2 (ja) 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
CN116478166A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
AU2017313085A1 (en) 2016-08-19 2019-03-14 Beigene Switzerland Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF
SG11201908560SA (en) 2017-03-16 2019-10-30 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
AR113796A1 (es) * 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
WO2020081450A1 (en) 2018-10-15 2020-04-23 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CN109438377B (zh) * 2018-12-13 2020-06-09 天津利安隆新材料股份有限公司 一种低温法制备含有醚键的长碳链三嗪类紫外线吸收剂的方法
EP3953346A1 (en) 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
AU2020278592A1 (en) 2019-05-17 2021-12-02 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
EP4055019A1 (en) * 2019-11-08 2022-09-14 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP7389905B2 (ja) * 2019-12-04 2023-11-30 河南知微生物医薬有限公司 ブルトン型チロシンキナーゼ阻害剤としてのイミダゾールカルボキサミド誘導体
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022562A1 (en) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
KR101357524B1 (ko) 2005-03-10 2014-02-03 질레드 코네티컷 인코포레이티드 특정 치환된 아미드, 그의 제조 방법, 및 사용 방법
WO2006124731A2 (en) 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0614804A2 (pt) 2005-08-09 2011-04-12 Irm Llc compostos e composições como inibidores de proteìna cinase
CA2620631A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-.receptor tyrosine kinases
JP2009507792A (ja) 2005-08-29 2009-02-26 バーテックス ファーマシューティカルズ インコーポレイテッド 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
US7786130B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
AU2007254491A1 (en) 2006-05-15 2007-11-29 Irm Llc Compositions and methods for FGF receptor kinases inhibitors
EP2261216A3 (en) 2006-07-24 2011-12-14 F. Hoffmann-La Roche AG Pyrazoles as glucokinase activators
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AR063707A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
EP2205564B1 (en) * 2007-10-23 2014-07-30 F. Hoffmann-La Roche AG Novel kinase inhibitors
CN101952283B (zh) 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
US7683064B2 (en) * 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
RU2505538C2 (ru) * 2008-02-05 2014-01-27 Ф.Хоффманн-Ля Рош Аг Новые пиридиноны и пиридазиноны
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
PE20100851A1 (es) * 2008-06-24 2011-01-31 Hoffmann La Roche PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
PE20110164A1 (es) * 2008-07-02 2011-03-28 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de quinasa
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2748414A1 (en) * 2009-04-24 2010-10-28 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
US8975260B2 (en) * 2010-09-01 2015-03-10 Genetech, Inc Pyridazinones, method of making, and method of use thereof
MX345170B (es) * 2011-05-17 2017-01-19 Hoffmann La Roche Inhibidores de la tirosina-cinasa de bruton.

Also Published As

Publication number Publication date
BR112013003114A2 (pt) 2016-06-28
CO6620025A2 (es) 2013-02-15
AU2011288489A1 (en) 2013-02-07
CA2807634A1 (en) 2012-02-16
MX2013001715A (es) 2013-03-22
ECSP13012437A (es) 2013-03-28
MA34465B1 (fr) 2013-08-01
US20130178461A1 (en) 2013-07-11
US8940741B2 (en) 2015-01-27
US20120040949A1 (en) 2012-02-16
JP2013533300A (ja) 2013-08-22
KR20130038420A (ko) 2013-04-17
SG187747A1 (en) 2013-03-28
JP5823518B2 (ja) 2015-11-25
CN103153984A (zh) 2013-06-12
EA201390207A1 (ru) 2013-08-30
HK1186186A1 (en) 2014-03-07
PE20131153A1 (es) 2013-10-05
ES2528371T3 (es) 2015-02-09
US8481540B2 (en) 2013-07-09
KR101546167B1 (ko) 2015-08-20
EP2603500B1 (en) 2014-11-19
WO2012020008A1 (en) 2012-02-16
EP2603500A1 (en) 2013-06-19
CL2013000391A1 (es) 2013-09-23
ZA201300705B (en) 2014-06-25
CN103153984B (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
AR082590A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR086403A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR092536A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR087543A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR072545A1 (es) Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias.
AR076066A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR070408A1 (es) Piridinonas y piridazinonas
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
ES2623982T3 (es) Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
AR058362A1 (es) Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos
AR074459A1 (es) Pirrolopirazinil-ureas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias.
AR072272A1 (es) Piridin-2-onas y piridazin-3-onas sustituidas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias causadas por una activacion aberrante de las celulas b, y composiciones farmaceuticas que las contienen.
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
PE20061164A1 (es) Piperazin-piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR061419A1 (es) Compuestos de piridil amida sustituidos como moduladores del receptor de histamida h3
EA200801828A3 (ru) Соединения 1,2,4,5- тетрагидро-3н-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica
AR072793A1 (es) Compuestos de aril isoxazol con actividades antitumorales
AR093123A1 (es) Inhibidores de la tirosina-quinasa de bruton
CO5650231A2 (es) Derivados de 1-(alquilaminoalquil-pirrolidin-/piperidinil)-2,2-difenilacetamida como antagonistas del receptor muscarinico, su procedimiento de sintesis y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure